- Home
- PRME vs CRGX Comparison
PRME vs CRGX Comparison
Compare PRME & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRME
- CRGX
- Stock Information
- Founded
- PRME 2019
- CRGX 2021
- Country
- PRME United States
- CRGX United States
- Employees
- PRME N/A
- CRGX N/A
- Industry
- PRME Medicinal Chemicals and Botanical Products
- CRGX
- Sector
- PRME Health Care
- CRGX
- Exchange
- PRME Nasdaq
- CRGX Nasdaq
- Market Cap
- PRME 191.7M
- CRGX 190.0M
- IPO Year
- PRME 2022
- CRGX 2023
- Fundamental
- Price
- PRME $2.71
- CRGX $4.20
- Analyst Decision
- PRME Buy
- CRGX Hold
- Analyst Count
- PRME 6
- CRGX 7
- Target Price
- PRME $9.38
- CRGX $4.67
- AVG Volume (30 Days)
- PRME 3.3M
- CRGX 591.0K
- Earning Date
- PRME 08-04-2025
- CRGX 08-11-2025
- Dividend Yield
- PRME N/A
- CRGX N/A
- EPS Growth
- PRME N/A
- CRGX N/A
- EPS
- PRME N/A
- CRGX N/A
- Revenue
- PRME $3,846,000.00
- CRGX N/A
- Revenue This Year
- PRME $104.12
- CRGX $57.81
- Revenue Next Year
- PRME $196.78
- CRGX N/A
- P/E Ratio
- PRME N/A
- CRGX N/A
- Revenue Growth
- PRME 550.76
- CRGX N/A
- 52 Week Low
- PRME $1.11
- CRGX $3.00
- 52 Week High
- PRME $6.75
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- PRME 69.76
- CRGX 44.13
- Support Level
- PRME $1.56
- CRGX $4.07
- Resistance Level
- PRME $2.78
- CRGX $4.31
- Average True Range (ATR)
- PRME 0.26
- CRGX 0.17
- MACD
- PRME 0.08
- CRGX -0.03
- Stochastic Oscillator
- PRME 76.81
- CRGX 18.62
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.